4/15
07:16 am
lptx
Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer [Yahoo! Finance]
High
Report
Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer [Yahoo! Finance]
4/15
07:00 am
lptx
Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer
High
Report
Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer
3/27
08:15 am
lptx
Leap Therapeutics, Inc. (NASDAQ: LPTX) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
High
Report
Leap Therapeutics, Inc. (NASDAQ: LPTX) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
3/26
04:35 pm
lptx
Micro Cap Soars Following Preliminary Data Update [Globe and Mail, The (Toronto, Canada)]
High
Report
Micro Cap Soars Following Preliminary Data Update [Globe and Mail, The (Toronto, Canada)]
3/26
01:44 pm
lptx
Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer [Yahoo! Finance]
Low
Report
Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer [Yahoo! Finance]
3/26
08:00 am
lptx
Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study [Yahoo! Finance]
Medium
Report
Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study [Yahoo! Finance]
3/26
08:00 am
lptx
Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
High
Report
Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
3/26
07:05 am
lptx
Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Medium
Report
Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
3/26
07:00 am
lptx
Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study
High
Report
Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study
1/30
07:27 am
lptx
Leap Therapeutics, Inc. (NASDAQ: LPTX) was downgraded by analysts at Baird R W from a "strong-buy" rating to a "hold" rating.
Medium
Report
Leap Therapeutics, Inc. (NASDAQ: LPTX) was downgraded by analysts at Baird R W from a "strong-buy" rating to a "hold" rating.
1/29
08:06 am
lptx
Leap Therapeutics, Inc. (NASDAQ: LPTX) was downgraded by analysts at Robert W. Baird from an "outperform" rating to a "neutral" rating. They now have a $1.25 price target on the stock, down previously from $9.00.
High
Report
Leap Therapeutics, Inc. (NASDAQ: LPTX) was downgraded by analysts at Robert W. Baird from an "outperform" rating to a "neutral" rating. They now have a $1.25 price target on the stock, down previously from $9.00.
1/29
08:06 am
lptx
Leap Therapeutics, Inc. (NASDAQ: LPTX) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating.
High
Report
Leap Therapeutics, Inc. (NASDAQ: LPTX) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating.